Core Insights - Aspira Women's Health Inc. has successfully completed the first development milestone of its ARPA-H award, receiving a cash payment of $2 million [1][4] - The company is set to receive a total of $10 million in funding over two years for its multi-marker blood test aimed at detecting endometriosis, which will utilize an AI-enabled algorithm [2][4] - The first milestone included initial launch activities and the development of project execution and risk mitigation plans, along with laboratory capability expansions [3][4] Funding and Milestones - Aspira has received a $2 million payment for achieving the first milestone and is entitled to an additional $1.5 million upon completing the second milestone [1][4] - The second milestone is expected to be completed in the first quarter of 2025 and will focus on expanding R&D capabilities and delivering additional product development plans [4] Product Development - The company is developing a non-invasive blood test for endometriosis, leveraging technology previously used in its ovarian cancer risk assessment tests [2][7] - Aspira's current ovarian cancer tests, OvaWatch and Ova1Plus, provide a comprehensive portfolio for assessing ovarian cancer risk, with OvaWatch having a negative predictive value of 99% [6] Market Position and Future Plans - Aspira aims to enhance the sensitivity and specificity of its tests by combining microRNA and protein biomarkers with patient data [7] - The ongoing development program for endometriosis aims to identify all forms of the disease, regardless of location or severity [7]
Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award